/
Oncology
Metastasis
69
Pipeline Programs↗
66
Active Trials↗
44
Companies Involved↗
Metastasis is a moderately active landscape with 69 programs across 44 companies. The most active players are Sihuan Pharmaceutical Holdings Group Ltd., Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd., Novartis. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical24
Phase 18
Phase 36
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
51 of 67 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 67 classified programs, each share of the total. Modality classified for 99% of 69 pipeline programs.
Analysis
Trial Status
182
clinical trials
Completed54 · 30%
Recruiting40 · 22%
Unknown status33 · 18%
Terminated16 · 9%
Not yet recruiting13 · 7%
Active, not recruiting12 · 7%
Other14 · 8%
Clinical Trials
Trial Activity
182 trials
Randomised Controlled Clinical Trial Investigating the Effect of Reduced Bleomycin in Elechtrochemotherapy Treatment on Patients With Cutaneous Malignancies (The BLESS Trial)
Recruiting·—·Approved·NCT06647342·55 enrolled
Dynamic Adaptive Radiotherapy for Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase: A Multicenter Randomized Controlled Trial Comparing Outcomes Between Proton Craniospinal Irradiation and Intrathecal Pemetrexed (DART-LM)
Recruiting·—·Preclinical·NCT07751536·84 enrolled
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate Via the Ommaya Reservoir in Breast Cancer With Leptomeningeal Metastasis: a Phase II Multicenter Clinical Trial
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06543992·22 enrolled
Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Recruiting·—·Phase 1·NCT06462508·30 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)